Cellular DNA content and survival in advanced ovarian carcinoma

✍ Scribed by Jacobus Pfisterer; Friedrich Kommoss; Willi Sauerbrei; Heike Renz; Andreas Du Bois; Marion Kiechle-Schwarz; Albrecht Pfleiderer

• Publisher: John Wiley and Sons
• Year: 1994
• Tongue: English
• Weight: 627 KB
• Volume: 74
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19941101)74:9<2509::aid-cncr2820740919>3.0.co;2-f

✦ Synopsis

Background. The prognosis of patients with advanced ovarian cancer is generally poor. To date, no satisfactory methods for predicting individual prognosis have been reported, especially in patients with little or no residual tumor after debulking.

Methods. The authors investigated in a retrospective study the prognostic significance of nuclear DNA content as measured by flow cytometry of the tumor specimens from 184 women with nonpreatreated International Federation of Gynecology and Obstetrics Stage 111 and IV ovarian cancer. Clearly defined inclusion criteria for the study population were used.

Results. Seventy-one (39%) cancers were diploid, whereas 113 (61%) were aneuploid. Ploidy showed a significant correlation with clinical and morphologic features such as age, histologic grade, serous histologic type, and residual tumor after debulking. No significant correlation was found between ploidy and ascites, estrogen-and progesterone receptor levels, and elevated pretreatment CA-125 levels. Univariate analysis showed significant correlations between overall survival and histologic grade (P = 0.003), patient age (P = 0.001), residual tumor after primary surgery ( P 4 0.001), stage ( P = 0.019) and ploidy (P = 0.009). Multivariate analysis revealed residual tumor (P < 0.001) and age (P = 0.051) to be associated independently with survival. Ploidy was not established as an independent prognostic factor.

Conclusions. These results suggest that abnormalities of the nuclear DNA content in advanced ovarian carcinomas are associated with various clinical and morphologic prognosticators, but that ploidy is not an independent prognostic factor for survival. Cancer 1994;74:

2509-15.